Update on posterior uveal melanoma

Treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease

Yevgeniy Shildkrot, Matthew Wilson

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Purpose of review: The current treatment options for posterior uveal melanoma and its metastases are reviewed in this paper. Recent developments in understanding genetic and molecular features of these tumors are discussed with emphasis on clinical application. Recent findings: The management of uveal melanomas has shifted to more eye-sparing approaches without significant improvement in patient survival. There has been an increased understanding of the genetic and molecular abnormalities that lead to melanomas that are more likely to metastasize. Treatments of metastatic disease remain inadequate.Uveal melanoma appears to be a systemic disease at presentation. Treatment of the primary disease may be curative in some patients. However, up to 50% of patients will ultimately succumb to the metastatic disease. The accuracy of patient prognostication can be enhanced by tumor cytogenetics. Even with this knowledge, no effective adjuvant treatments exist. Further research and innovation will allow tailored therapies for patients with high-risk tumor features.

Original languageEnglish (US)
Pages (from-to)504-510
Number of pages7
JournalCurrent Opinion in Ophthalmology
Volume20
Issue number6
DOIs
StatePublished - Nov 1 2009

Fingerprint

Molecular Biology
Therapeutics
Neoplasms
Cytogenetics
Melanoma
Uveal melanoma
Neoplasm Metastasis
Survival
Research

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Update on posterior uveal melanoma : Treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. / Shildkrot, Yevgeniy; Wilson, Matthew.

In: Current Opinion in Ophthalmology, Vol. 20, No. 6, 01.11.2009, p. 504-510.

Research output: Contribution to journalReview article

@article{2497714f8798489fad8ac4edaafde9ae,
title = "Update on posterior uveal melanoma: Treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease",
abstract = "Purpose of review: The current treatment options for posterior uveal melanoma and its metastases are reviewed in this paper. Recent developments in understanding genetic and molecular features of these tumors are discussed with emphasis on clinical application. Recent findings: The management of uveal melanomas has shifted to more eye-sparing approaches without significant improvement in patient survival. There has been an increased understanding of the genetic and molecular abnormalities that lead to melanomas that are more likely to metastasize. Treatments of metastatic disease remain inadequate.Uveal melanoma appears to be a systemic disease at presentation. Treatment of the primary disease may be curative in some patients. However, up to 50{\%} of patients will ultimately succumb to the metastatic disease. The accuracy of patient prognostication can be enhanced by tumor cytogenetics. Even with this knowledge, no effective adjuvant treatments exist. Further research and innovation will allow tailored therapies for patients with high-risk tumor features.",
author = "Yevgeniy Shildkrot and Matthew Wilson",
year = "2009",
month = "11",
day = "1",
doi = "10.1097/ICU.0b013e328330b549",
language = "English (US)",
volume = "20",
pages = "504--510",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Update on posterior uveal melanoma

T2 - Treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease

AU - Shildkrot, Yevgeniy

AU - Wilson, Matthew

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Purpose of review: The current treatment options for posterior uveal melanoma and its metastases are reviewed in this paper. Recent developments in understanding genetic and molecular features of these tumors are discussed with emphasis on clinical application. Recent findings: The management of uveal melanomas has shifted to more eye-sparing approaches without significant improvement in patient survival. There has been an increased understanding of the genetic and molecular abnormalities that lead to melanomas that are more likely to metastasize. Treatments of metastatic disease remain inadequate.Uveal melanoma appears to be a systemic disease at presentation. Treatment of the primary disease may be curative in some patients. However, up to 50% of patients will ultimately succumb to the metastatic disease. The accuracy of patient prognostication can be enhanced by tumor cytogenetics. Even with this knowledge, no effective adjuvant treatments exist. Further research and innovation will allow tailored therapies for patients with high-risk tumor features.

AB - Purpose of review: The current treatment options for posterior uveal melanoma and its metastases are reviewed in this paper. Recent developments in understanding genetic and molecular features of these tumors are discussed with emphasis on clinical application. Recent findings: The management of uveal melanomas has shifted to more eye-sparing approaches without significant improvement in patient survival. There has been an increased understanding of the genetic and molecular abnormalities that lead to melanomas that are more likely to metastasize. Treatments of metastatic disease remain inadequate.Uveal melanoma appears to be a systemic disease at presentation. Treatment of the primary disease may be curative in some patients. However, up to 50% of patients will ultimately succumb to the metastatic disease. The accuracy of patient prognostication can be enhanced by tumor cytogenetics. Even with this knowledge, no effective adjuvant treatments exist. Further research and innovation will allow tailored therapies for patients with high-risk tumor features.

UR - http://www.scopus.com/inward/record.url?scp=74249098795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249098795&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e328330b549

DO - 10.1097/ICU.0b013e328330b549

M3 - Review article

VL - 20

SP - 504

EP - 510

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 6

ER -